“We are honored to draw on the expertise of these industry leaders as we continue to pursue our mission of creating a better patient experience for those with challenging chronic and acute surgical wounds, while simultaneously improving value for both payors and medical practices,” stated
Arch welcomes the following six members to its
- Dr.
Gregory A. Bohn , MD, FACS, ABPM/UHM, MAPWCA, CWSP, board-certified in General Surgery and Hyperbaric Medicine, and President of the AmericanBoard of Wound Healing ; - Dr.
Matthew G. Garoufalis , DPM, FASPS, FACPM, CWS, board-certified in Podiatric Medicine and Foot and Ankle Surgery, Chief Medical Officer ofAdvanced Oxygen Therapy Inc. , and key opinion leader on diabetic foot care, lower extremity wound care, and limb salvage; - Dr.
John C. Lantis , MD, FACS, Chief and Professor of Surgery atMount Sinai West Hospital and theIcahn School of Medicine , and key opinion leader on limb salvage and lower extremity wound healing; - Dr.
Brock A. Liden , DPM, FABWH, FAPWCA, board-certified in Podiatry, attending physician at WAFL, and expert lecturer on wound care, podiatric medicine, surgery, and practice management; and, - Dr.
Terry A. Treadwell , MD, FACS is a vascular surgeon, Medical Director of theInstitute of Advanced Wound Care inMontgomery, Alabama , and renowned lecturer on chronic wound care.
About
Located in
For more information, please visit archtherapeutics.com or follow us on Twitter, Instagram, and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to satisfy our existing obligations and continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the
Contact:
ARTH Investor Relations
Toll Free: +1.855.340.ARTH (2784) (US and
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Chief Financial Officer
Phone: 617.431.2333
Email: mabrams@archtherapeutics.com
1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of
Source:
2023 GlobeNewswire, Inc., source